Radiosensitizing Pancreatic Cancer with PARP Inhibitor and Gemcitabine: An In Vivo and a Whole-Transcriptome Analysis after Proton or Photon Irradiation

Radiosensitizing Pancreatic Cancer with PARP Inhibitor and Gemcitabine: An In Vivo and a Whole-Transcriptome Analysis after Proton or Photon Irradiation

Over the past few years, studies have focused on the development of targeted radiosensitizers such as poly(ADP-ribose) polymerase inhibitors. We performed an in vivo study and a whole-transcriptome analysis to determine whether PARP inhibition enhanced gemcitabine-based chemoradiosensitization of pa...

Full description

Bibliographic Details
Main Authors: Waisse Waissi, Anaïs Nicol, Matthieu Jung, Marc Rousseau, Delphine Jarnet, Georges Noel, Hélène Burckel
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:Cancers
Subjects:
pancreatic cancer
proton therapy
radiotherapy
DNA repair
gemcitabine
PARP inhibitor
Online Access:https://www.mdpi.com/2072-6694/13/3/527

Internet

https://www.mdpi.com/2072-6694/13/3/527

Similar Items